Hedgehog (Hh) signaling represents a critical developmental pathway that continues to play important roles in adult brain function. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of Hedgehog signaling contributes to neuronal vulnerability, impaired neurogenesis, and progressive neurodegeneration. This section examines the role of Hedgehog pathway dysregulation in CBS/PSP pathogenesis and explores therapeutic implications. [1]
CBS and PSP are distinct clinical syndromes sharing common pathological features of 4R tau accumulation 1. While CBS presents with asymmetric cortical dysfunction and basal ganglia degeneration leading to apraxia, alien limb phenomena, and cortical sensory loss, PSP is characterized by vertical gaze palsy, postural instability, and axial rigidity with progressive gait disturbance. Understanding the role of Hedgehog signaling in these conditions may reveal novel therapeutic targets. [2]
The Hedgehog pathway's involvement in CBS/PSP extends beyond its developmental functions. In the adult brain, this signaling cascade regulates neural progenitor cell proliferation, neuronal survival, synaptic plasticity, and glial cell function. Dysregulation of these processes contributes to the progressive neurodegeneration observed in both disorders. [3]
Three Hedgehog ligands exist in mammals: Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh) 2. Sonic hedgehog is the most extensively studied in the context of neurobiology and neurodegeneration. [4]
Shh undergoes autocatalytic cleavage to generate an N-terminal signaling domain (Shh-N) and a C-terminal domain involved in cholesterol modification and multimerization 3. The palmitoylation of Shh at its N-terminus further enhances its signaling potency and trafficking capabilities. This modification is essential for proper pathway activation in the central nervous system. [5]
In the adult brain, Shh is expressed by various cell types including neurons, astrocytes, and oligodendrocyte lineage cells. The ligand can act in both paracrine and autocrine fashions, and its expression is dynamically regulated in response to injury and disease states. This adaptive regulation makes the pathway particularly relevant to neurodegenerative disease processes. [6]
The Hedgehog pathway involves a precisely orchestrated cascade of protein interactions: [7]
Patched-1 (PTCH1): Twelve-transmembrane domain receptor that serves as the pathway's negative regulator. In the absence of Hedgehog ligand, PTCH1 inhibits Smoothened through direct protein-protein interaction. [8]
Smoothened (SMO): Seven-transmembrane domain GPCR family member that transduces the Hedgehog signal upon pathway activation. SMO localizes to primary cilia, where it initiates downstream signaling cascades. [9]
Gli transcription factors: Three Gli proteins (Gli1, Gli2, Gli3) serve as the terminal effectors. In the absence of signaling, Gli proteins are phosphorylated by PKA, CK1, and GSK3β, leading to proteolytic processing into transcriptional repressors. Upon pathway activation, active Gli proteins translocate to the nucleus. [10]
Suppressor of Fused (SUFU): Negative regulator that sequesters Gli proteins in the cytoplasm. SMO activation promotes SUFU dissociation, allowing Gli nuclear translocation.
Hedgehog signaling plays essential roles in adult neurogenesis 4:
The continuous generation of new neurons in the adult brain is crucial for cognitive function, mood regulation, and brain repair. Hedgehog signaling provides the mitogenic signals necessary for neural stem cell proliferation and the transcriptional programs for neuronal differentiation.
Shh signaling exerts neuroprotective effects through multiple mechanisms 5:
These neuroprotective functions are particularly important in the context of tauopathies, where neurons face chronic stress from protein aggregation, mitochondrial dysfunction, and neuroinflammation.
Hedgehog signaling also regulates glial cell function:
Studies suggest Hedgehog pathway dysregulation in CBS/PSP 6:
The motor cortex and basal ganglia, regions prominently affected in CBS, show particular alterations in Hedgehog pathway components. Immunohistochemical studies demonstrate decreased Shh immunoreactivity in neurons with 4R tau inclusions, suggesting a direct relationship between tau pathology and Hedgehog dysfunction.
Hedgehog signaling interacts with tau pathology in several ways:
The relationship between Hedgehog signaling and tau pathology creates a vicious cycle: tau pathology impairs Hedgehog signaling, which reduces neuroprotection and neurogenesis, leading to further tau accumulation and spread.
The pattern of Hedgehog dysregulation in CBS/PSP follows the regional distribution of tau pathology:
Therapeutic strategies targeting Hedgehog signaling include 7:
The development of brain-penetrant Hedgehog pathway modulators represents an active area of research. Small molecule SMO agonists have shown promise in preclinical models of Parkinson's disease and may have applicability to CBS/PSP.
Given the complex pathophysiology of CBS/PSP, Hedgehog-targeted therapies may be most effective in combination:
Challenges in Hedgehog-targeted therapy include 8:
Promising approaches include:
Armstrong MJ, et al. 'Corticobasal syndrome: a review of clinical features and diagnosis'. Neuropsychologia. 2020. ↩︎
Litvan I, et al. [ Clinical features and management of corticobasal syndrome](https://doi.org/10.1016/S1474-4422(20). Lancet Neurology. 2020. ↩︎
Boxer AL, et al. 'Comparison of PSP and CBS phenotypes: a prospective imaging study'. Neurology. 2020. ↩︎
Kovacs GG, et al. Staging of tau pathology in PSP. Acta Neuropathologica. 2022. ↩︎
Williams DR, et al. 'Tau pathology in PSP: burden and distribution'. Brain. 2021. ↩︎
Stamelou M, et al. Motor phenotypes and biomarkers in tauopathies. Neurobiology of Aging. 2021. ↩︎
Chahine LM, et al. Biomarkers for tauopathies in CBS/PSP. Neurobiology of Aging. 2020. ↩︎
Jellinger KA. 'Functional neuropathology of PSP: neural network dysfunction'. Acta Neuropathologica. 2020. ↩︎
Lee HG, et al. The role of tau oligomers in neurodegenerative diseases. Acta Neuropathologica Communications. 2014. ↩︎
Mandelkow EM, et al. Tau pathology and neurodegeneration. Journal of Alzheimer's Disease. 2010. ↩︎